Reply to the comment on: “Dalbavancin for infective endocarditis: a systematic review of effectiveness, safety, and dosing” - Anastasios E Chaldoupis; Vasilios Petrakis; Petros Ioannou; Konstantina A Tsante; Deny Tsakri; Aglaia Domouchtsidou; Stella Baliou; Marianna Vlachaki; Alexandra Mpakosi; Sotirios P Fortis; George Samonis; Rozeta Sokou; et al. (European Journal of Clinical Microbiology & Infectious Diseases, 2026)